Test Price
2,800 AED✅ Home Collection Available
SETX Gene Amyotrophic Lateral Sclerosis Type 4 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post‑test clinical guidance for result interpretation by DHA‑licensed clinical geneticists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731; we handle prior approval with major UAE insurers.
Test Overview & Methodology
The SETX Gene NGS Test identifies pathogenic variants in the senataxin gene associated with ALS Type 4 (juvenile-onset slow-progressing ALS), enabling precise diagnosis, prognosis assessment, and informed family planning. This analysis uses next-generation sequencing (NGS) with 99.9% sensitivity, performed in our ISO 9001:2015‑certified diagnostic laboratory in Dubai, UAE. A pre‑test genetic counselling session is mandatory. Our genetic counsellors will draw a detailed three‑generation pedigree chart, review your clinical history, and explain possible outcomes, ensuring fully informed consent. No fasting is required for blood draw. Sample options: 2 mL of whole blood (EDTA tube), extracted DNA (≥1 µg), or a dried blood spot (one drop on FTA card).
| Feature | Our NGS SETX Test | Sanger Sequencing (Closest Alternative) |
|---|---|---|
| Method | Next‑Generation Sequencing (NGS) | Sanger Sequencing (targeted) |
| Coverage | Full coding exons ±20 bp flanking regions | Hotspot regions only; may miss novel variants |
| Sensitivity | >99.9% for single nucleotide variants & small indels | >99.5% for targeted sites; cannot detect large rearrangements |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks |
| Clinical Utility | Comprehensive; enables carrier testing & family screening | Limited to known familial mutation follow‑up |
| Price (AED) | 2,800 | 1,800–2,200 |
Physician Insight & Safety Protocols
“A genetic test provides crucial molecular evidence, yet it must always be correlated with clinical presentation and family history. A pathogenic SETX variant supports the diagnosis of ALS type 4, but comprehensive neurological evaluation remains essential. The results guide prognosis and family counselling, not immediate treatment changes. Always discuss findings with your managing specialist before making any medical decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
Do not discontinue prescribed medication or alter your treatment based solely on this test result. Always consult your managing physician before making any changes. This genetic information is one component of a broader diagnostic workup and should not be used as the sole basis for therapeutic decisions.
Safety Information & Exclusion Criteria
- Not suitable for patients with acute febrile illness or severe anaemia (Hb <8 g/dL) that may compromise sample quality.
- Minors must be accompanied by a legal guardian; parental consent is mandatory per UAE Federal Law No. 2 of 2019 concerning health data protection.
- Individuals unable to understand and provide informed consent must have a legally authorised representative.
- Emergency Red Flags: If you experience sudden limb weakness, difficulty breathing, choking, or rapid worsening of symptoms, do not wait for test results — seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What is the SETX Gene ALS Type 4 NGS Test used for?
This test detects mutations in the senataxin gene responsible for juvenile-onset amyotrophic lateral sclerosis type 4, aiding definitive diagnosis, prognosis, and family risk assessment. It is recommended for individuals with early‑onset, slowly progressive motor neuron disease or a family history of ALS. A positive result confirms the genetic subtype and may guide targeted research or future therapies. We use full‑gene sequencing to identify both known and novel variants. If you are asymptomatic but have a family mutation, this test can determine carrier status.
2. How is the test performed and what sample is required?
A simple blood draw, extracted DNA sample, or a single drop of dried blood on an FTA card is collected by a certified phlebotomist at your home or our clinic. The sample is transported under strict cold‑chain conditions to our ISO‑certified laboratory. Sequencing is performed using NGS, and results are interpreted by board‑certified clinical geneticists. Turnaround time is 3 to 4 weeks. You need to complete a pre‑test genetic counselling session to ensure appropriate sample selection and documentation.
3. Can this be used for asymptomatic family members?
Yes, once a disease‑causing mutation is identified in the family, asymptomatic relatives can be tested to clarify carrier status and reproductive risks. Predictive testing requires extensive counselling and strict adherence to UAE PDPL data privacy regulations. For minors, testing is only permitted with parental consent and a clear clinical benefit, in line with Federal Law No. 2 of 2019. Our genetic counsellors will guide you through the ethical and psychological considerations before any sample is taken.
UAE Regulatory & Data Privacy Adherence
- ✅ Licensed by Dubai Health Authority (DHA) – Facility License: 1143
- ✅ Certified: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
- ✅ Compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- ✅ Safety and clinical consent governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- ✅ Primary Specialists Involved: Clinical Geneticist, Genetic Counsellor, Neurologist
*Price is indicative and may vary based on sample type and insurance coverage. Always consult a qualified healthcare professional for personal medical advice.
Clinical & Logistical Metadata
| Test Name | SETX Gene Amyotrophic Lateral Sclerosis Type 4 Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA (≥1 µg), or Dried Blood Spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full coding exons ±20 bp flanking regions |
| ICD-10-CM Code | G12.21 |
| LOINC Code | 94219-1 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians